ADC Therapeutics (ADCT) Total Non-Current Liabilities (2019 - 2026)

ADC Therapeutics has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $489.4 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $489.4 million, down 3.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $489.4 million (down 3.35% YoY), and the FY2025 annual result was $509.0 million, down 2.53% from the prior year.
• Total Non-Current Liabilities came in at $489.4 million for Q1 2026 at ADC Therapeutics, down from $509.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $522.2 million in Q4 2024 to a low of $341.5 million in Q4 2022.
• The 5-year median for Total Non-Current Liabilities is $506.3 million (2025), against an average of $491.0 million.
• Across the five-year window, Total Non-Current Liabilities retreated 9.65% in 2022 and soared 44.71% in 2023, its largest moves.
• ADC Therapeutics' Total Non-Current Liabilities stood at $341.5 million in 2022, then jumped by 44.71% to $494.2 million in 2023, then gained by 5.67% to $522.2 million in 2024, then decreased by 2.53% to $509.0 million in 2025, then decreased by 3.85% to $489.4 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $489.4 million (Q1 2026), $509.0 million (Q4 2025), and $518.5 million (Q3 2025), per Business Quant data.